🇺🇸 FDA
Pipeline program

tulisokibart, Placebo to MK-7240

MK-7240-015

Phase 2 small_molecule active

Quick answer

tulisokibart, Placebo to MK-7240 for Psoriatic arthritis​​ is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Psoriatic arthritis​​
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials